{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:24Z","timestamp":1776408684405,"version":"3.51.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06909-1","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:32:38Z","timestamp":1772771558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced dose versus standard melphalan conditioning for autologous stem cell transplantation in multiple myeloma: a single-center retrospective study"],"prefix":"10.1007","volume":"105","author":[{"given":"Yifan","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"5","key":"6909_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA et al (2022) Diagnosis and management of multiple myeloma: A review. JAMA 327(5):464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003","journal-title":"JAMA"},{"key":"6909_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3238\/arztebl.2016.0470","volume":"113","author":"C Gerecke","year":"2016","unstructured":"Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S (2016) The diagnosis and treatment of multiple myeloma. Deutsches Arzteblatt Int 113:27\u201328. https:\/\/doi.org\/10.3238\/arztebl.2016.0470","journal-title":"Deutsches Arzteblatt Int"},{"issue":"12","key":"6909_CR3","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/s1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M et al (2021) Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (forte): A randomised, open-label, phase 2 trial. Lancet Oncol 22(12):1705\u20131720. https:\/\/doi.org\/10.1016\/s1470-2045(21)00535-0","journal-title":"Lancet Oncol"},{"issue":"2","key":"6909_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS et al (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387(2):132\u2013147. https:\/\/doi.org\/10.1056\/NEJMoa2204925","journal-title":"N Engl J Med"},{"issue":"6","key":"6909_CR5","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/s2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA et al (2020) Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (emn02\/ho95): A multicentre, randomised, open-label, phase 3 study. Lancet Haematol 7(6):e456\u2013e68. https:\/\/doi.org\/10.1016\/s2352-3026(20)30099-5","journal-title":"Lancet Haematol"},{"issue":"14","key":"6909_CR6","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M et al (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376(14):1311\u20131320. https:\/\/doi.org\/10.1056\/NEJMoa1611750","journal-title":"N Engl J Med"},{"key":"6909_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-134538","volume":"136","author":"A Perrot","year":"2020","unstructured":"Perrot A, Lauwers-Cances V, Cazaubiel T, Facon T, Caillot D, Clement-Filliatre L et al (2020) Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: Long-term follow-up analysis of the ifm 2009 trial. Blood 136:39. https:\/\/doi.org\/10.1182\/blood-2020-134538","journal-title":"Blood"},{"issue":"1","key":"6909_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/bmt.2015.211","volume":"51","author":"WI Bensinger","year":"2016","unstructured":"Bensinger WI, Becker PS, Gooley TA, Chauncey TR, Maloney DG, Gopal AK et al (2016) A randomized study of melphalan 200\u00a0mg\/m(2) vs 280\u00a0mg\/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-sct. Bone Marrow Transpl 51(1):67\u201371. https:\/\/doi.org\/10.1038\/bmt.2015.211","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"6909_CR9","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","volume":"115","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M et al (2010) Melphalan 200\u00a0mg\/m(2) versus melphalan 100\u00a0mg\/m(2) in newly diagnosed myeloma patients: A prospective, multicenter phase 3 study. Blood 115(10):1873\u20131879. https:\/\/doi.org\/10.1182\/blood-2009-09-241737","journal-title":"Blood"},{"issue":"4","key":"6909_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/1078155217697486","volume":"24","author":"E Aypar","year":"2018","unstructured":"Aypar E, \u0130zzettin FV, Ak\u0131 \u015e Z, Sancar M, Ye\u011fin ZA, T\u00fcrk\u00f6z-Sucak G (2018) Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. J Oncol Pharm Pract 24(4):281\u2013289. https:\/\/doi.org\/10.1177\/1078155217697486","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"6909_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.v99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al (2002) Comparison of 200\u00a0mg\/m(2) melphalan and 8 gy total body irradiation plus 140\u00a0mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the intergroupe francophone du my\u00e9lome 9502 randomized trial. Blood 99(3):731\u2013735. https:\/\/doi.org\/10.1182\/blood.v99.3.731","journal-title":"Blood"},{"issue":"1","key":"6909_CR12","doi-asserted-by":"publisher","first-page":"26847","DOI":"10.1038\/s41598-024-78350-1","volume":"14","author":"MJ Jeon","year":"2024","unstructured":"Jeon MJ, Yu ES, Kim DS, Lee BH, Lee SR, Sung HJ et al (2024) Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and\/or immunomodulatory drug treatment. Sci Rep 14(1):26847. https:\/\/doi.org\/10.1038\/s41598-024-78350-1","journal-title":"Sci Rep"},{"issue":"9","key":"6909_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nrclinonc.2010.104","volume":"7","author":"S Giralt","year":"2010","unstructured":"Giralt S (2010) 200\u00a0mg\/m(2) melphalan\u2013the gold standard for multiple myeloma. Nat Rev Clin Oncol 7(9):490\u2013491. https:\/\/doi.org\/10.1038\/nrclinonc.2010.104","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"6909_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ejh.13690","volume":"107","author":"C Straka","year":"2021","unstructured":"Straka C, Salwender H, Knop S, Vogel M, M\u00fcller J, Metzner B et al (2021) Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. Eur J Haematol 107(5):529\u2013542. https:\/\/doi.org\/10.1111\/ejh.13690","journal-title":"Eur J Haematol"},{"issue":"5","key":"6909_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41409-020-01170-0","volume":"56","author":"A Brioli","year":"2021","unstructured":"Brioli A, vom Hofe F, Rucci P, Ernst T, Yomade O, Hilgendorf I et al (2021) Melphalan 200\u00a0mg\/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients. Bone Marrow Transpl 56(5):1209\u20131212. https:\/\/doi.org\/10.1038\/s41409-020-01170-0","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"6909_CR16","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1080\/10428194.2023.2213366","volume":"64","author":"N Sharma","year":"2023","unstructured":"Sharma N, Benson E, Zhao Q, Nunnelee J, Cottini F, Elder P et al (2023) Survival outcomes following autologous stem cell transplant with melphalan 140\u00a0mg\/m(2) versus 200\u00a0mg\/m(2) preparative regimens in patients with multiple myeloma. Leuk Lymphoma 64(7):1315\u20131321. https:\/\/doi.org\/10.1080\/10428194.2023.2213366","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6909_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3324\/haematol.2017.181339","volume":"103","author":"HW Auner","year":"2018","unstructured":"Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH et al (2018) Melphalan 140\u00a0mg\/m(2) or 200\u00a0mg\/m(2) for autologous transplantation in myeloma: Results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (calm) study. A report by the ebmt chronic malignancies working party. Haematologica 103(3):514\u2013521. https:\/\/doi.org\/10.3324\/haematol.2017.181339","journal-title":"Haematologica"},{"issue":"12","key":"6909_CR18","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.3324\/haematol.2021.279179","volume":"106","author":"SA Srour","year":"2021","unstructured":"Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M et al (2021) Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211\u20133214. https:\/\/doi.org\/10.3324\/haematol.2021.279179","journal-title":"Haematologica"},{"issue":"9","key":"6909_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.clml.2024.05.005","volume":"24","author":"Z Brown","year":"2024","unstructured":"Brown Z, Scott C, Zhang LF, Sadek R, Clarke A, Jillella A et al (2024) Assessing outcomes in patients with multiple myeloma postautologous stem cell transplantation: Contrasting the effects of melphalan dosages at 200\u00a0mg\/m(2) versus 140\u00a0mg\/m(2). Clinical lymphoma. myeloma Leuk 24(9):642\u2013647. https:\/\/doi.org\/10.1016\/j.clml.2024.05.005","journal-title":"myeloma Leuk"},{"issue":"7","key":"6909_CR20","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/j.clml.2025.02.004","volume":"25","author":"J Kort","year":"2025","unstructured":"Kort J, Naleid N, Oley F, Ignatz-Hoover J, Margevicius S, Fu P et al (2025) Melphalan 140 mg\/m(2) is safe and effective for frail and older multiple myeloma patients with comparable rates of minimal residual disease negativity. Clin lymphoma myeloma Leuk 25(7):e443. https:\/\/doi.org\/10.1016\/j.clml.2025.02.004","journal-title":"Clin lymphoma myeloma Leuk"},{"issue":"4","key":"6909_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","volume":"9","author":"R Al Hamed","year":"2019","unstructured":"Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M (2019) Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J 9(4):44. https:\/\/doi.org\/10.1038\/s41408-019-0205-9","journal-title":"Blood Cancer J"},{"issue":"4","key":"6909_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.23736\/s0031-0808.20.04114-2","volume":"62","author":"G Ricciuti","year":"2020","unstructured":"Ricciuti G, Falcone A, Cascavilla N, Martinelli G, Cerchione C (2020) Autologous stem cell transplantation in multiple myeloma. Panminerva Med 62(4):220\u2013224. https:\/\/doi.org\/10.23736\/s0031-0808.20.04114-2","journal-title":"Panminerva Med"},{"issue":"11","key":"6909_CR23","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41409-020-0916-3","volume":"55","author":"AS Al Saleh","year":"2020","unstructured":"Al Saleh AS, Sidiqi MH, Lee J, Dispenzieri A, Muchtar E, Buadi FK et al (2020) Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transpl 55(11):2132\u20132137. https:\/\/doi.org\/10.1038\/s41409-020-0916-3","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"6909_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/bmt.2014.56","volume":"49","author":"SR Parmar","year":"2014","unstructured":"Parmar SR, Bookout R, Shapiro JF, Tombleson R, Perkins J, Kim J et al (2014) Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Bone Marrow Transpl 49(6):761\u2013766. https:\/\/doi.org\/10.1038\/bmt.2014.56","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"6909_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-0609.2012.01795.x","volume":"89","author":"G Talamo","year":"2012","unstructured":"Talamo G, Rakszawski KL, Rybka WB, Dolloff NG, Malysz J, Berno T et al (2012) Effect of time to infusion of autologous stem cells (24 vs. 48\u00a0h) after high-dose melphalan in patients with multiple myeloma. Eur J Haematol 89(2):145\u2013150. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01795.x","journal-title":"Eur J Haematol"},{"issue":"24","key":"6909_CR26","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/jco-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF et al (2025) International myeloma society\/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma. J Clin oncology: official J Am Soc Clin Oncol 43(24):2739\u20132751. https:\/\/doi.org\/10.1200\/jco-24-01893","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"7","key":"6909_CR27","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/s1470-2045(23)00223-1","volume":"24","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ et al (2023) Management of multiple myeloma-related renal impairment: Recommendations from the international myeloma working group. Lancet Oncol 24(7):e293\u2013e311. https:\/\/doi.org\/10.1016\/s1470-2045(23)00223-1","journal-title":"Lancet Oncol"},{"issue":"1","key":"6909_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41408-025-01286-w","volume":"15","author":"X Lu","year":"2025","unstructured":"Lu X, Andersen EF, Banerjee R, Eno CC, Gonzales PR, Kumar S et al (2025) Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: A report of the cancer genomics consortium plasma cell neoplasm working group. Blood Cancer J 15(1):86. https:\/\/doi.org\/10.1038\/s41408-025-01286-w","journal-title":"Blood Cancer J"},{"issue":"4","key":"6909_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjh.13608","volume":"171","author":"HW Auner","year":"2015","unstructured":"Auner HW, Garderet L, Kr\u00f6ger N (2015) Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. Br J Haematol 171(4):453\u2013462. https:\/\/doi.org\/10.1111\/bjh.13608","journal-title":"Br J Haematol"},{"issue":"1","key":"6909_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-024-01481-2","volume":"24","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang X, Zou Z, Xiong Y, Gu X, Zou R et al (2024) Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: A critical appraisal of the pre-antibody era. Clin experimental Med 24(1):215. https:\/\/doi.org\/10.1007\/s10238-024-01481-2","journal-title":"Clin experimental Med"},{"issue":"3","key":"6909_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ejh.13804","volume":"109","author":"A Rago","year":"2022","unstructured":"Rago A, Annibali O, Tomarchio V, Coppetelli U, Fazio F, Cupelli L et al (2022) Autologous stem cell transplantation in multiple myeloma patients over 70 years: A gimema lazio working group experience in a retrospective case-control study. Eur J Haematol 109(3):250\u2013256. https:\/\/doi.org\/10.1111\/ejh.13804","journal-title":"Eur J Haematol"},{"issue":"5","key":"6909_CR32","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41409-020-01159-9","volume":"56","author":"I Vaxman","year":"2021","unstructured":"Vaxman I, Visram A, Kumar S, Dispenzieri A, Buadi F, Dingli D et al (2021) Autologous stem cell transplantation for multiple myeloma patients aged\u2009\u2265\u200975 treated with novel agents. Bone Marrow Transpl 56(5):1144\u20131150. https:\/\/doi.org\/10.1038\/s41409-020-01159-9","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"6909_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1177\/1078155220987623","volume":"28","author":"KE Kowalski","year":"2022","unstructured":"Kowalski KE, Wheeler SE, Adams CB, Voils SA, Richards AI (2022) Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation. J Oncol Pharm Pract 28(2):274\u2013281. https:\/\/doi.org\/10.1177\/1078155220987623","journal-title":"J Oncol Pharm Pract"},{"key":"6909_CR34","doi-asserted-by":"publisher","unstructured":"Poczta A, Rogalska A, Marczak A (2021) Treatment of multiple myeloma and the role of melphalan in the era of modern therapies-current research and clinical approaches. J Clin Med 10(9). https:\/\/doi.org\/10.3390\/jcm10091841","DOI":"10.3390\/jcm10091841"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06909-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06909-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06909-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:10Z","timestamp":1776405550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06909-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6909"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06909-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the Medical Ethics Committee of Huazhong University of Science and Technology. The study followed the Declaration of Helsinki, and all participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}